These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 33813384

  • 1. Evaluation of the Role of p95 HER2 Isoform in Trastuzumab Efficacy in Metastatic Breast Cancer.
    Rigakos G, Razis E, Koliou GA, Oikonomopoulos G, Tsolaki E, Sperinde J, Chrisafi S, Zarkavelis G, Pazarli E, Batistatou A, Kourea HP, Papakostas P, Bafaloukos D, Asimakopoulou NI, Res E, Kotsakis A, Pectasides D, Koutras A, Christodoulou C, Fountzilas G.
    Anticancer Res; 2021 Apr; 41(4):1793-1802. PubMed ID: 33813384
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study.
    Koutras A, Lazaridis G, Koliou GA, Kouvatseas G, Christodoulou C, Pectasides D, Kotoula V, Batistatou A, Bobos M, Tsolaki E, Papadopoulou K, Pentheroudakis G, Papakostas P, Pervana S, Petraki K, Chrisafi S, Razis E, Psyrri A, Bafaloukos D, Kalogeras KT, Kalofonos HP, Fountzilas G.
    PLoS One; 2018 Apr; 13(12):e0207707. PubMed ID: 30521571
    [Abstract] [Full Text] [Related]

  • 3. p95-HER2 and trastuzumab resistance in metastatic breast cancer; is immunohistochemistry appropriate?
    Kocar M, Bozkurtlar E, Telli F, Yumuk F, Kaya H, Kocar H, Serdar Turhal N.
    J BUON; 2014 Apr; 19(1):245-9. PubMed ID: 24659671
    [Abstract] [Full Text] [Related]

  • 4. Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies.
    Tural D, Serdengecti S, Demirelli F, Öztürk T, İlvan S, Turna H, Özgüroglu M, Büyükünal E.
    Br J Cancer; 2014 Apr 15; 110(8):1968-76. PubMed ID: 24595002
    [Abstract] [Full Text] [Related]

  • 5. PTEN, Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer.
    Duman BB, Sahin B, Acikalin A, Ergin M, Zorludemir S.
    J BUON; 2013 Apr 15; 18(1):44-50. PubMed ID: 23613387
    [Abstract] [Full Text] [Related]

  • 6. p95HER2 Methionine 611 Carboxy-Terminal Fragment Is Predictive of Trastuzumab Adjuvant Treatment Benefit in the FinHer Trial.
    Sperinde J, Huang W, Vehtari A, Chenna A, Kellokumpu-Lehtinen PL, Winslow J, Bono P, Lie YS, Petropoulos CJ, Weidler J, Joensuu H.
    Clin Cancer Res; 2018 Jul 01; 24(13):3046-3052. PubMed ID: 29535130
    [Abstract] [Full Text] [Related]

  • 7. High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance).
    Chumsri S, Sperinde J, Liu H, Gligorov J, Spano JP, Antoine M, Moreno Aspitia A, Tan W, Winslow J, Petropoulos CJ, Chenna A, Bates M, Weidler JM, Huang W, Dueck A, Perez EA.
    Clin Cancer Res; 2018 Jul 01; 24(13):3053-3058. PubMed ID: 29530935
    [Abstract] [Full Text] [Related]

  • 8. HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer.
    Lipton A, Goodman L, Leitzel K, Cook J, Sperinde J, Haddad M, Köstler WJ, Huang W, Weidler JM, Ali S, Newton A, Fuchs EM, Paquet A, Singer CF, Horvat R, Jin X, Banerjee J, Mukherjee A, Tan Y, Shi Y, Chenna A, Larson J, Lie Y, Sherwood T, Petropoulos CJ, Williams S, Winslow J, Parry G, Bates M.
    Breast Cancer Res Treat; 2013 Aug 01; 141(1):43-53. PubMed ID: 23959396
    [Abstract] [Full Text] [Related]

  • 9. Predictive significance of HER2 intratumoral heterogeneity, determined by simultaneous gene and protein analysis, for resistance to trastuzumab-based treatments for HER2-positive breast cancer.
    Horii R, Nitta H, Nojima M, Maruyama R, Ueno T, Ito Y, Ohno S, Banks P, Kanda H, Akiyama F.
    Virchows Arch; 2021 Jul 01; 479(1):13-21. PubMed ID: 33496805
    [Abstract] [Full Text] [Related]

  • 10. Expression of truncated HER2 and its prognostic value in HER2-positive breast cancer patients.
    Maria AM, El-Shebiney M, El-Saka AM, Zamzam Y.
    J Egypt Natl Canc Inst; 2018 Jun 01; 30(2):49-55. PubMed ID: 29779938
    [Abstract] [Full Text] [Related]

  • 11. Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab.
    Nishimura R, Toh U, Tanaka M, Saimura M, Okumura Y, Saito T, Tanaka T, Teraoka M, Shimada K, Katayama K, Koga T, Kurashita K, Hasegawa S, Todoroki H, Kai Y, Ohi Y, Toyoshima S, Arima N, Mitsuyama S, Tamura K.
    Oncology; 2017 Jun 01; 93(1):51-61. PubMed ID: 28478451
    [Abstract] [Full Text] [Related]

  • 12. The interaction between carcinoembryonic antigen-related cell adhesion molecule 6 and human epidermal growth factor receptor 2 is associated with therapeutic efficacy of trastuzumab in breast cancer.
    Iwabuchi E, Miki Y, Kanai A, Miyashita M, Kijima G, Hirakawa H, Suzuki T, Ishida T, Sasano H.
    J Pathol; 2018 Nov 01; 246(3):379-389. PubMed ID: 30058236
    [Abstract] [Full Text] [Related]

  • 13. Quantitative measurements of tumoral p95HER2 protein expression in metastatic breast cancer patients treated with trastuzumab: independent validation of the p95HER2 clinical cutoff.
    Duchnowska R, Sperinde J, Chenna A, Haddad M, Paquet A, Lie Y, Weidler JM, Huang W, Winslow J, Jankowski T, Czartoryska-Arłukowicz B, Wysocki PJ, Foszczyńska-Kłoda M, Radecka B, Litwiniuk MM, Zok J, Wiśniewski M, Zuziak D, Biernat W, Jassem J.
    Clin Cancer Res; 2014 May 15; 20(10):2805-13. PubMed ID: 24668646
    [Abstract] [Full Text] [Related]

  • 14. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J, Kanomata N, Yamashita T, Shimo T, Mizutoh A, Moriya T, Sonoo H.
    Breast Cancer; 2015 May 15; 22(3):292-9. PubMed ID: 23749689
    [Abstract] [Full Text] [Related]

  • 15. Recent Insights into the Development of Preclinical Trastuzumab- Resistant HER2+ Breast Cancer Models.
    Gonzalez-Alonso P, Cristobal I, Zazo S, Martin-Aparicio E, Chamizo C, Madoz-Gurpide J, Rovira A, Eroles P, Lluch A, Albanell J, Rojo F.
    Curr Med Chem; 2018 May 15; 25(17):1976-1998. PubMed ID: 27993109
    [Abstract] [Full Text] [Related]

  • 16. Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer.
    Guarneri V, Dieci MV, Frassoldati A, Maiorana A, Ficarra G, Bettelli S, Tagliafico E, Bicciato S, Generali DG, Cagossi K, Bisagni G, Sarti S, Musolino A, Ellis C, Crescenzo R, Conte P.
    Oncologist; 2015 Sep 15; 20(9):1001-10. PubMed ID: 26245675
    [Abstract] [Full Text] [Related]

  • 17. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
    Wildiers H, Tryfonidis K, Dal Lago L, Vuylsteke P, Curigliano G, Waters S, Brouwers B, Altintas S, Touati N, Cardoso F, Brain E.
    Lancet Oncol; 2018 Mar 15; 19(3):323-336. PubMed ID: 29433963
    [Abstract] [Full Text] [Related]

  • 18. CTMP, a predictive biomarker for trastuzumab resistance in HER2-enriched breast cancer patient.
    Chen YC, Li HY, Liang JL, Ger LP, Chang HT, Hsiao M, Calkins MJ, Cheng HC, Chuang JH, Lu PJ.
    Oncotarget; 2017 May 02; 8(18):29699-29710. PubMed ID: 27447863
    [Abstract] [Full Text] [Related]

  • 19. MicroRNA-21 as a predictor and prognostic factor for trastuzumab therapy in human epidermal growth factor receptor 2-positive metastatic breast cancer.
    Badr M, Said H, Louka ML, Elghazaly HA, Gaballah A, Atef Abd El Mageed M.
    J Cell Biochem; 2019 Mar 02; 120(3):3459-3466. PubMed ID: 30246355
    [Abstract] [Full Text] [Related]

  • 20. Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study.
    Filipits M, Dafni U, Gnant M, Polydoropoulou V, Hills M, Kiermaier A, de Azambuja E, Larsimont D, Rojo F, Viale G, Toi M, Harbeck N, Prichard KI, Gelber RD, Dinh P, Zardavas D, Leyland-Jones B, Piccart-Gebhart MJ, Dowsett M, TransHERA investigators.
    Clin Cancer Res; 2018 Jul 01; 24(13):3079-3086. PubMed ID: 29530933
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.